摘要
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations.
学科与关键词
- Current state of CAR-T therapy for T-cell malignanciesLuo, Liangkui; Zhou, Xuan; Zhou, Lijuan; Liang, Zhao; Yang, Jilong; Tu, Sanfang*; Li, Yuhua*Therapeutic Advances in Hematology, 2022, 13: 20406207221143025.被引 6
- Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategiesXiao, Xinyi; Huang, Shengkang; Chen, Sifei; Wang, Yazhuo; Sun, Qihang; Xu, Xinjie*; Li, Yuhua*JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40(1): 367.被引 60
- Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological MalignanciesLiu, Qianzhen; Liu, Zengping; Wan, Rongxue*; Huang, Wenhua*Cancers, 2022, 14(18): 4452.被引 2
